Literature DB >> 8752165

Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.

T Tsukui1, A Hildesheim, M H Schiffman, J Lucci, D Contois, P Lawler, B B Rush, A T Lorincz, A Corrigan, R D Burk, W Qu, M A Marshall, D Mann, M Carrington, M Clerici, G M Shearer, D P Carbone, D R Scott, R A Houghten, J A Berzofsky.   

Abstract

Human papillomavirus (HPV) is believed to be the major cause of cervical cancer. To investigate whether a cellular immune response, especially a T helper type 1 response, is related to the natural defense against HPV-related cervical lesions, the interleukin 2 response of peripheral blood lymphocytes in vitro to overlapping peptides from HPV-16 E6 and E7 oncoproteins was compared with the degree of cervical cytological abnormality among 140 women in a cross-sectional study. We compared 66 women diagnosed with low-grade squamous intraepithelial lesions (LSIL), 21 with high-grade squamous intraepithelial lesions (HSIL), and 28 with invasive cervical cancer with 25 women who were cytologically normal but previously HPV-16 DNA positive. The fraction showing strong interleukin 2 production against HPV-16 peptides was greatest among cytologically normal women (35%) and declined with increasing disease severity [LSIL] (20%), HSIL, (17%), and cancer patients (7%); X2 test P for the trend = 0.02], whereas the responses against a recall influenza antigen were not significantly different among groups. Our finding suggests that a T helper lymphocyte type 1 response to HPV antigens is associated with disease status. This result may reflect a targeted effect of the disease on immune function or a protective effect of the immune response against disease progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

Authors:  N R Chu; H B Wu; T Wu; L J Boux; M I Siegel; L A Mizzen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 4.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission.

Authors:  B K Patterson; A Landay; J Andersson; C Brown; H Behbahani; D Jiyamapa; Z Burki; D Stanislawski; M A Czerniewski; P Garcia
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

6.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 7.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

8.  A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma.

Authors:  Chen Chen; Jiajie Hou; Zhe Lin; Ming Yao; Runqiu Jiang; Youjing Wang; Yun Gao; Qing Shao; Lei Deng; Yun Chen; Beicheng Sun
Journal:  Cell Mol Immunol       Date:  2013-05-20       Impact factor: 11.530

9.  The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.

Authors:  Maria Alice G Gonçalves; Edson G Soares; Eduardo A Donadi
Journal:  Infect Agent Cancer       Date:  2009-08-18       Impact factor: 2.965

10.  Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.

Authors:  A D Santin; S Bellone; A Ravaggi; J J Roman; S Pecorelli; G P Parham; M J Cannon
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.